ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Gastroenterology Edition: Top Headlines for Week of October 24, 2022"
Episode Synopsis
In this edition, AGA speaks out on controversial NordICC data; first US patient enrolled in phase 3 trial of obefazimod; 'unprecedented' shift in hepatitis A outbreaks and more. Read the full coverage here: AGA speaks out on controversial NordICC data citing modest colonoscopy benefit for CRC First US patient enrolled in Abivax's phase 3 trial of obefazimod for ulcerative colitis Shift in hepatitis A outbreaks 'unprecedented' in HAV vaccine era, CDC reports AGA releases first guideline ranking most effective anti-obesity medications Inflammatory bowel disease may be causal risk for psoriasis, psoriatic arthritis References: Bretthauer M, et al. NEJM. 2022;doi:10.1056/NEJMoa2208375. Foster MA, et al. MMWR Morb Mortal Wkly Rep. 2022;doi:10.15585/mmwr.mm7139a1. Freuer D, et al. JAMA Dermatol. 2022;doi:10.1001/jamadermatol.2022.3682. Grunvuld E, et al. Gastroenterology. 2022; doi: 10.1053/j.gastro.2022.08.045. Press release
In God we trust